(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 14.79% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.99%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Ani Pharmaceuticals's revenue in 2026 is $923,706,000.On average, 10 Wall Street analysts forecast ANIP's revenue for 2026 to be $26,020,831,408, with the lowest ANIP revenue forecast at $24,565,120,560, and the highest ANIP revenue forecast at $27,567,524,184. On average, 10 Wall Street analysts forecast ANIP's revenue for 2027 to be $29,136,962,442, with the lowest ANIP revenue forecast at $26,043,576,890, and the highest ANIP revenue forecast at $32,526,039,260.
In 2028, ANIP is forecast to generate $31,661,710,944 in revenue, with the lowest revenue forecast at $26,680,450,386 and the highest revenue forecast at $35,187,260,654.